Aptorum Group 30% Higher Premarket After FDA Orphan Drug Designation
21 January 2022 - 01:11AM
Dow Jones News
By Michael Dabaie
Aptorum Group Ltd. shares rose 30%, to $1.59, premarket after
the clinical-stage biopharmaceutical company said the U.S. Food and
Drug Administration granted orphan drug designation to SACT-1.
The designation is for the treatment of patients with
neuroblastoma. Neuroblastoma is one of the most prevailing solid
tumor cancers in children, representing 8% to 10% of all childhood
tumors, the company said.
Aptorum Group plans to file an investigational new drug
application to begin a phase 1b/2a clinical trial for SACT-1 to
test the drug in neuroblastoma patients in 2022.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
January 20, 2022 08:56 ET (13:56 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Mar 2023 to Mar 2024